Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
18452310
DOI
10.1021/bi702086w
Knihovny.cz E-resources
- MeSH
- Models, Biological MeSH
- Insulin chemistry metabolism MeSH
- Rats MeSH
- Humans MeSH
- Lipogenesis MeSH
- Magnetic Resonance Spectroscopy MeSH
- Rats, Wistar MeSH
- Swine MeSH
- Receptor, Insulin metabolism MeSH
- Protein Structure, Tertiary MeSH
- Adipose Tissue metabolism MeSH
- Adipocytes metabolism MeSH
- Protein Binding MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Insulin MeSH
- Receptor, Insulin MeSH
In this study, we prepared several shortened and full-length insulin analogues with substitutions at position B26. We compared the binding affinities of the analogues for rat adipose membranes with their ability to lower the plasma glucose level in nondiabetic Wistar rats in vivo after subcutaneous administration, and also with their ability to stimulate lipogenesis in vitro. We found that [NMeHisB26]-DTI-NH 2 and [NMeAlaB26]-DTI-NH 2 were very potent insulin analogues with respect to their binding affinities (214 and 465%, respectively, compared to that of human insulin), but they were significantly less potent than human insulin in vivo. Their full-length counterparts, [NMeHisB26]-insulin and [NMeAlaB26]-insulin, were less effective than human insulin with respect to binding affinity (10 and 21%, respectively) and in vivo activity, while [HisB26]-insulin exhibited properties similar to those of human insulin in all of the tests we carried out. The ability of selected analogues to stimulate lipogenesis in adipocytes was correlated with their biological potency in vivo. Taken together, our data suggest that the B26 residue and residues B26-B30 have ambiguous roles in binding affinity and in vivo activity. We hypothesize that our shortened analogues, [NMeHisB26]-DTI-NH 2 and [NMeAlaB26]-DTI-NH 2, have different modes of interaction with the insulin receptor compared with natural insulin and that these different modes of interaction result in a less effective metabolic response of the insulin receptor, despite the high binding potency of these analogues.
References provided by Crossref.org
A radioligand binding assay for the insulin-like growth factor 2 receptor
Rational steering of insulin binding specificity by intra-chain chemical crosslinking
Structural integrity of the B24 site in human insulin is important for hormone functionality
Non-equivalent role of inter- and intramolecular hydrogen bonds in the insulin dimer interface